Summary: This article presents a review of recent major advances in precision oncology and the future implications of these advances, specifying the iterative progress achieved from the end of 2022 through 2023. We discuss the different classes of precision oncology drugs and associated biomarkers as well as the improvements in clinical trial design that have enabled the efficient testing of these drugs.

中文翻译：

---

精准肿瘤学：2023 年回顾


摘要：本文回顾了精准肿瘤学的最新重大进展以及这些进展的未来影响，具体说明了从 2022 年底到 2023 年取得的迭代进展。我们讨论了不同类别的精准肿瘤药物和相关生物标志物，以及临床试验设计的改进使得这些药物的测试变得有效。